SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors pending FDA decision on deramiocel for Duchenne muscular dystrophy is driving attention, with traders focused on the Nov. 22 PDUFA date, the amended upper-limb data and new commercial-launch job postings they interpret as possible signs of readiness. Approval hopes and short-squeeze speculation are prominent, while skeptics note that hiring does not confirm an FDA outcome and cite the companys prior regulatory setback and remaining efficacy questions.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS REGAL Phase 3 leukemia trial reached its prespecified event threshold, triggering final analysis and putting the GPS survival readout in focus. Traders are sharply divided over whether GPS will show a benefit or whether control-arm outcomes and trial assumptions could undermine the bull case, amid volatile trading and speculation about short positioning.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCaths Medicare add-on reimbursement could decline after the first quarter of 2027 has raised concerns about pricing and revenue for CorMedixs flagship product, amid a sharp selloff. Traders are split between viewing the comments as a serious commercial risk and arguing they are preliminary and at odds with CMS estimates; many also criticize managements silence, while some are buying the dip.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios accelerated FDA approval of a treatment for recurrent respiratory papillomatosis has renewed focus on competition with Precigens PAPZIMEOS, which is already approved for the same disease. Traders are divided over how much market share the new entrant could threaten, with some calling the selloff an overreaction and pointing to Precigens head start and different approval status.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A steep tech-led selloff has focused discussion on fears that heavy AI infrastructure spending may not produce adequate returns, alongside concerns about persistent inflation and higher interest rates. Traders are divided on whether the drop marks an oversold buying opportunity or signals further losses, with debate also citing weak tech outlooks and volatile trading.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX is drawing attention for its breakout ahead of the expected Q3 earnings report, with traders focused on BRIUMVIs growth and possible further upside. Buyout and short-squeeze chatter is prominent but speculative; some traders instead attribute the move to earnings expectations and the companys commercial momentum.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regenerons strong third-quarter earnings, fueled by Eylea HD sales and higher Sanofi collaboration revenue from Dupixent, drove a sharp share-price jump and breakout discussion. Traders largely welcomed the results, while some debated whether newer drugs can sustain growth; the upcoming cemdisiran decision also drew attention.

Spdr Dow Jones Industrial Average ETF Trust - Spdr Dow Jones Industrial Average ETF Trust

A broad market selloff is driving discussion, with traders pointing to tech earnings and doubts about AI spending returns alongside renewed Iran tensions and rising oil as sources of pressure. The tone is heavily bearish, with many traders favoring puts, though others argue the weakness is a rotation or pullback and look for a rebound.

SPDR Gold Shares Tokenized ETF (Robinhood) (GLD) is a cryptocurrency and operates on the Robinhood Chain platform. SPDR Gold Shares Tokenized ETF (Robinhood) has a current supply of 0. The last known price of SPDR Gold Shares Tokenized ETF (Robinhood) is 355.59611392 USD and is down -3.18 over the last 24 hours. It is currently trading on 39 active market(s) with $3,035,916.41 traded over the last 24 hours. More information can be found at https://robinhood.com/us/en/.

GoldCoin

Golds sharp selloff and break below a key support level dominate discussion, with traders linking pressure to hawkish Fed rate expectations, higher yields and a firmer dollar. Some see oversold conditions and are buying the dip, while others warn the technical breakdown could bring further losses.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovins steep selloff ahead of its earnings report is driving discussion, with traders citing analyst price-target cuts and worries about growth, competition, and weakness in the broader ad market. Some expect those concerns to weigh on results, while others argue the decline is disconnected from the companys profitability and see the report as a potential sentiment test.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
